Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CRYZ | Q08257 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perfosfamide SCHEMBL1650261 | 1.00 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL28131626 | 0.95 | NPSR1 (0.48) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL5089114 | 0.91 | NPSR1 (0.66) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL28091536 | 0.90 | NPSR1 (0.44) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL28091534 | 0.90 | NPSR1 (0.44) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL10412920 | 0.85 | NPSR1 (0.53) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Pipobroman SCHEMBL27849441 | 0.84 | KDM4E (0.38) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Pipobroman SCHEMBL7100695 | 0.84 | KDM4E (0.38) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL10413698 | 0.83 | NPSR1 (0.47) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL17897647 | 0.82 | NPSR1 (0.46) | NPSR1KDM4EALOX15MAPK1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12824 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4120980-B1 | METHOD FOR WRAPPING A SANITARY ITEM OR A STACK COMPRISING A NUMBER OF SANITARY ITEMS | BW CONVERTING GMBH (DE) | 2025-10-22 | — | — | EP | claimed |
| US-12448559-B1 | Puddle job with delayed setting of resin via a polymerization reaction with an activator | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-10-21 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| CN-1679947-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1660438-A | Slow released anticancer combination of medication embedded the interior of the body | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-08-31 | — | — | CN | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| US-6482802-B1 | Use of neomycin for treating angiogenesis-related diseases | ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. | 2002-11-19 | — | — | US | claimed |
| EP-1083896-A4 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT FOR RES IN HUMAN BIO (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| EP-1083896-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-1999058126-B1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT RES INHUMAN BIOLOGY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |